AI Article Synopsis
- Isolated myeloid sarcoma (MS) is a rare form of acute myeloid leukemia (AML) that occurs outside the bone marrow, and its outcomes are not well understood due to its rarity.
- A study analyzed data from the SEER database, identifying 345 patients diagnosed with isolated MS between 1973 and 2010 to compare survival rates between MS and non-MS AML patients.
- Results showed that the 3-year survival rate for MS was 31.9%, significantly higher than the 17.2% for non-MS AML, with survival rates varying based on the disease's primary site, with certain locations showing better outcomes than others.
Article Abstract
Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diagnosed with isolated MS between 1973 and 2010. Overall survival (OS) was calculated and compared between MS and non-MS AML using the log-rank test. Survival was also evaluated based upon the primary site of disease presentation. The 3-year survival rate for MS (0.319; 95% confidence interval [CI]: 0.267-0.371) was greater than for non-MS AML (0.172; 95% CI: 0.168-0.175). There was variation in survival based on the site of involvement. The survival rates for isolated MS involving the pelvis/genitourinary organs, eyes/gonads and gastrointestinal mucosa appeared to be slightly improved when compared to primary sites of soft tissues, lymphatic/hematopoietic tissues or nervous system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2014.963080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Less adequate cardiorespiratory fitness (CRF) is associated with several aspects of Alzheimer's disease (AD) pathology, including neuroinflammation, neurodegeneration and synaptic dysfunction, all of which are known contributors to the clinical outcome - progressive cognitive decline [1]. AD-associated biomolecular changes also seem to be attenuated in carriers of the functionally advantageous variant of the KLOTHO gene (KL-VS) [2]. While KL-VS and CRF both appear to mitigate aspects of AD pathology, they have been exclusively studied in isolation.
View Article and Find Full Text PDF[Disseminated toxoplasmosis after cord blood transplantation diagnosed at autopsy].
Rinsho Ketsueki
January 2025
Department of Hematology and Oncology, Tokai University School of Medicine.
A 54-year-old woman underwent cord blood transplantation in second remission of acute myeloid leukemia. She tested positive for anti-toxoplasma IgG antibody before transplantation. After neutrophil engraftment, she complained of foggy vision, but brain MRI showed no abnormality.
View Article and Find Full Text PDFEffects of the pan-caspase inhibitor Q-VD-OPh on human neutrophil lifespan and function.
PLoS One
January 2025
Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, Missouri, United States of America.
Human neutrophils are abundant, short-lived leukocytes that turn over at a rate of approximately 1011 cells/day via a constitutive apoptosis program. Certain growth factors, inflammatory mediators and infectious agents can delay apoptosis or induce neutrophils to die by other mechanisms. Nonetheless, a large body of data demonstrates that apoptosis of untreated neutrophils typically ensues within 24 hours of cell isolation and in vitro culture.
View Article and Find Full Text PDFPaeoniflorin sensitizes imatinib mesylate-resistant chronic myeloid leukemia cells via the inhibition of Cyr61 production.
Anticancer Drugs
January 2025
Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
Imatinib mesylate (IM) is a first-line therapy for chronic myeloid leukemia (CML) and exhibits good therapeutic effects, but not in all patients with CML owing to drug resistance. Our previous study showed that Cyr61 plays a key role in IM resistance in CML cells. Paeoniflorin (PF) is a bioactive compound isolated from the traditional Chinese medicine Paeonia lactiflora Pall that displays anticancer activity.
View Article and Find Full Text PDFModulatory Effect of Cucurbitacin D from on ZNF217 Oncogene Expression in NPM-Mutated Acute Myeloid Leukemia.
Pharmaceuticals (Basel)
November 2024
Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
The expression of oncogene zinc-finger protein 217 (ZNF217) has been reported to play a central role in cancer development, resistance, and recurrence. Therefore, targeting ZNF217 has been proposed as a possible strategy to fight cancer, and there has been much research on compounds that can target ZNF217. The present work investigates the chemo-preventive properties of cucurbitacin D, a compound with a broad range of anticancer effects, in hematological cancer cells, specifically with regard to its ability to modulate ZNF217 expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!